【査読付き英文論文】

*1. Fukagawa A, Arai Y, Maeshima A, Hama N, Totoki Y, Nakamura H, Saito-Adachi M, Hokazono Y, Nakamura E, Matsui Y, Adachi S, Hamamoto R, Ushiku T, Yachida S, Shibata T. Proteomic Analysis Identifies Potential Biomarkers of ELOC-Mutated Renal Cell Carcinoma. Am J Surg Pathol. 2026 Jul 13. doi: 10.1097/PAS.0000000000002583. Online ahead of print. [pubmed]

*2. Higashiyama RI, Yoshida T, Shiraishi K, Miyakoshi J, Torasawa M, Shirasawa M, Masuda K, Shinno Y, Matsumoto Y, Okuma Y, Yoshida Y, Goto Y, Horinouchi H, Tuchida T, Hamamoto R, Yamamoto N, Watanabe SI, Yatabe Y, Kohno T, Ohe Y. Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer. Br J Cancer. 2026 Jun 2. doi: 10.1038/s41416-026-03457-3. Online ahead of print. [pubmed]

*3. Nakamura M, Hayami S, Miyamoto A, Suzaki N, Yoshimura T, Nakamura K, Shigekawa Y, Shimizu A, Kitahata Y, Takeuchi A, Motobayashi H, Matsumoto K, Ehata S, Hamamoto R, Kawai M. SMYD2 regulates lymph node metastasis derived from intrahepatic cholangiocellular carcinoma through CCR7-dependent chemotaxis. Sci Rep. 2026 Jun 1. doi: 10.1038/s41598-026-55155-y. Online ahead of print. [pubmed]

*4. Takahashi S, Takahashi M, Kinoshita M, Miyake M, Kawaguchi R, Shinojima N, Mukasa A, Saito K, Nagane M, Otani R, Higuchi F, Tanaka S, Hata N, Tamura K, Tateishi K, Nishikawa R, Arita H, Nonaka M, Uda T, Fukai J, Okita Y, Tsuyuguchi N, Kanemura Y, Tsushima F, Kakeda S, Akashi T, Taoka T, Watanabe Y, Yamada K, Hirai T, Azuma M, Yoshiura T, Sese J, Ichimura K, Narita Y, Hamamoto R. Comparing artificial intelligence and physician performance in predicting IDH mutation status in glioma. NPJ Digit Med. 2026 May 5;9(1):528. [pubmed]

*5. Suzuki-Ariyoshi E, Kaneko S, Sone K, Ikawa N, Hachijo R, Jonouchi Y, Tsuboyama N, Taguchi A, Asada K, Komatsu M, Iriyama T, Oda K, Osuga Y, Hirota Y, Hamamoto R. SETD8 promotes ovarian clear cell carcinoma by epigenetically activating RNA metabolism genes via H4K20me1. Sci Rep. 2026 Apr 15;16(1):17597. [pubmed]

*6. Suzaki N, Hayami S, Miyamoto A, Nakamura M, Yoshimura T, Nakamura K, Shigekawa Y, Shimizu A, Kitahata Y, Takeuchi A, Motobayashi H, Osada S, Ehata S, Hamamoto R, Kawai M. Impact of SETD8/KMT5A overexpression on hepatocellular carcinoma progression and prognosis. PLoS One. 2026 Apr 13;21(4):e0337503. [pubmed]

*7. Machida E, Takamizawa Y, Takayanagi D, Cho H, Shida D, Yamada M, Asami Y, Ono H, Takeuchi M, Hamamoto R, Rikiyama T, Suzuki K, Kanemitsu Y, Kohno T, Takashima A, Sekine S, Shiraishi K. Microbiomic and immunogenic biomarkers of adjuvant chemotherapy efficacy in stage III colorectal cancer. JNCI Cancer Spectr. 2026 May 9;10(3):pkag036. [pubmed]

*8. Teraya N, Komatsu M, Takeda K, Shozu K, Harada N, Komatsu R, Sakai A, Aoyama R, Kaneko M, Asada K, Kaneko S, Iwamoto K, Nakashima A, Matsuoka R, Sekizawa A, Hamamoto R. Artificial Intelligence-Based Automated Assessment of the Four-Chamber View in Fetal Cardiac Ultrasound Videos. Bioengineering (Basel). 2026 Mar 5;13(3):303. [pubmed]

*9. Hamamoto R, Koyama T, Takahashi S, Yasuda Y, Kobayashi K, Akagi Y, Kouno N, Sudo K, Hirata M, Sunami K, Kubo T, Katayama H, Takashima A, Taniguchi T, Matsumoto H, Shibaki R, Asada K, Komatsu M, Kaneko S, Yamada M, Horinouchi H, Tanaka K, Goto Y, Kato K, Saito Y, Nakamura K, Yamamoto N. Implementing generative artificial intelligence in precision oncology: safety, governance, and significance. J Hematol Oncol. 2026 Feb 9;19(1):14. [pubmed]

*10. Yamaguchi M, Higuchi D, Yoshida H, Fujii E, Kobayashi Kato M, Hiranuma K, Asami Y, Ono H, Koyama T, Komatsu M, Hamamoto R, Matsumoto K, Sekizawa A, Terao Y, Kohno T, Kato T, Makinoshima H, Ishikawa M, Shiraishi K. Metabolomic and transcriptomic analyses identify metabolic alterations and immune suppression in hypermetabolic ovarian cancer. Sci Rep. 2026 Feb 5;16(1):7429. [pubmed]

*11. Takemura C, Miyake M, Kobayashi K, Matsumoto H, Shibaki R, Urikura A, Goto Y, Yatabe Y, Watanabe SI, Sone M, Kusumoto M, Hamamoto R, Watanabe H. A clinically applicable and generalizable deep learning model for anterior mediastinal tumors in CT images across multiple institutions. Sci Rep. 2026 Jan 30;16(1):6774. [pubmed]

*12. Miyabe M, Arimitsu S, Bolatkan A, Machino H, Hamamoto R, Asada K. Deciphering RNA and protein expression discordance identifies TOP2A as a prognostic biomarker and potential therapeutic target in lung adenocarcinoma. Discov Oncol. 2026 Jan 28;17(1):170. [pubmed]

*13. Komatsu R, Komatsu M, Takeda K, Harada N, Teraya N, Wakisaka S, Natsume T, Taniguchi T, Aoyama R, Kaneko M, Iwamoto K, Matsuoka R, Sekizawa A, Hamamoto R. Three-Dimensional Visualization and Detection of the Pulmonary Venous-Left Atrium Connection Using Artificial Intelligence in Fetal Cardiac Ultrasound Screening. Bioengineering (Basel). 2026 Jan 15;13(1):100. [pubmed]

*14. Hashiguchi H, Kouno N, Komatsu M, Shiino S, Takehara N, Takeda K, Takahashi S, Hsiao YW, Murata T, Obama K, Takayama S, Pharoah PDP, Hamamoto R. Validation of the postoperative prognostication tool PREDICT version 2.2 and 3.0 using data from the National cancer center hospital in Japan. Breast Cancer. 2026 Mar;33(2):415-425. [pubmed]